Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI.

Trial Profile

Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Thrombosis
  • Focus Therapeutic Use
  • Acronyms APACS-HPR
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 Oct 2013 Accrual to date is 23% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top